Researchers warn of inconsistency in asthma data in EHRs

Researchers from Swansea University Medical School in the United Kingdom and the Asthma UK Centre for Applied Research have raised concerns about the quality of asthma diagnoses in patients' electronic health records (EHRs). A study, published in European Respiratory Journal, outlined current practices used to diagnose asthma with suggestions for improvements on standards.

Improving the quality of recorded asthma in patients EHRs starts with clearly outlining the standards to define the condition. The study analyzed 113 research articles for the algorithms used to define asthma, the severity of patient’s conditions and exacerbations from EHRs.

Results showed that 106 algorithms did not have justified validity, which increased the consistency in asthma reporting. The lack of consensus on the definition and outcomes of asthma reporting makes identifying and treating patients more difficult. With the many differing algorithms, researchers caution the reproducibility of research on asthma until a clear set of standards is set.

"This study highlights a long known problem and one that desperately needs to be resolved,” Samantha Walker, director of research and policy and deputy chief executive at Asthma UK. “The data held on electronic health records has the potential to be of great value to asthma research, our overall understanding of asthma development, and development of new treatments. However, wide variations in how asthma is defined and recorded mean that these data sets are difficult to use for these purposes. As electronic health records become more widely used, it is vital to ensure all the information is defined and collected in a consistent manner so that we can have confidence in it. Until this happens we are missing opportunities to understand asthma fully and make improvements in asthma care."

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Updated compensation data includes good news for multiple subspecialties. The new report also examines private equity's impact on employment models and how much male cardiologists earn compared to females.

When drugs are on the FDA’s shortage list, outsourcing facilities can produce their own compounded versions. When the FDA removed tirzepatide from that list with no warning, it created a considerable amount of chaos both behind the scenes and in pharmacies all over the country. 

Trimed Popup
Trimed Popup